Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise

Muscle and Nerve

Volumn 44, Issue 6, 2011, Pages 882-889

  Meador, Benjamin M ^a   Huey, Kimberly A ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b DRAKE UNIVERSITY   (United States)

Author keywords

Caspase; Creatine kinase; Heat shock protein; HMG CoA reductase inhibitor; Muscle function

Indexed keywords

CASPASE; CASPASE 3; CASPASE 9; CERIVASTATIN; CREATINE KINASE; CRYSTALLIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 25; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALPHA B CRYSTALLIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; EXERCISE; FORCE; GASTROCNEMIUS MUSCLE; ISOMETRIC EXERCISE; MALE; MOUSE; MUSCLE FATIGUE; MUSCLE FUNCTION; MUSCLE MASS; MYOPATHY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RUNNING; SEDENTARY LIFESTYLE; SKELETAL MUSCLE; STRESS;

ANIMALS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MUSCLE CONTRACTION; MUSCLE FATIGUE; MUSCLE, SKELETAL; OXIDATIVE STRESS; PHYSICAL CONDITIONING, ANIMAL;

EID: 81555206669     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22236     Document Type: Article

References (54)

1. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006;291:C1208-C1212.
2. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-414.
3. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-295.
4. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22:441-457.
5. Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol 2002;40:163-171.
6. Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther 2005;85:459-465.
7. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005;25:2560-2566.
8. Seachrist JL, Loi CM, Evans MG, Criswell KA, Rothwell CE. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicol Sci 2005;88:551-561.
9. Balnave CD, Thompson MW. Effect of training on eccentric exercise-induced muscle damage. J Appl Physiol 1993;75:1545-1551.
10. Brown SJ, Child RB, Day SH, Donnelly AE. Exercise-induced skeletal muscle damage and adaptation following repeated bouts of eccentric muscle contractions. J Sports Sci 1997;15:215-222.
11. Mair J, Mayr M, Muller E, Koller A, Haid C, Artner-Dworzak E, et al. Rapid adaptation to eccentric exercise-induced muscle damage. Int J Sports Med 1995;16:352-356.
12. Huey KA, Meador BM. Contribution of IL-6 to the Hsp72, Hsp25, and alphaB-crystallin [corrected] responses to inflammation and exercise training in mouse skeletal and cardiac muscle. J Appl Physiol 2008;105:1830-1836.
13. Siu PM, Bryner RW, Martyn JK, Alway SE. Apoptotic adaptations from exercise training in skeletal and cardiac muscles. FASEB J 2004;18:1150-1152.
14. Koh TJ, Escobedo J. Cytoskeletal disruption and small heat shock protein translocation immediately after lengthening contractions. Am J Physiol Cell Physiol 2004;286:C713-C722.
15. Paulsen G, Lauritzen F, Bayer ML, Kalhovde JM, Ugelstad I, Owe SG, et al. Subcellular movement and expression of HSP27, alphaBcrystallin, and HSP70 after two bouts of eccentric exercise in humans. J Appl Physiol 2009;107:570-582.
16. Paulsen G, Vissing K, Kalhovde JM, Ugelstad I, Bayer ML, Kadi F, et al. Maximal eccentric exercise induces a rapid accumulation of small heat shock proteins on myofibrils and a delayed HSP70 response in humans. Am J Physiol Regul Integr Comp Physiol 2007; 293:R844-R853.
17. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz- Latoud C, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nature Cell Biol 2000;2:645-652.
18. Akbar MT, Lundberg AM, Liu K, Vidyadaran S, Wells KE, Dolatshad H, et al. The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death. J Biol Chem 2003;278:19956-19965.
19. Choi DH, Ha JS, Lee WH, Song JK, Kim GY, Park JH, et al. Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett 2007;581:1649-1656.
20. Lee WC, Wen HC, Chang CP, Chen MY, Lin MT. Heat shock protein 72 overexpression protects against hyperthermia, circulatory shock, and cerebral ischemia during heatstroke. J Appl Physiol 2006; 100:2073-2082.
21. Morrison LE, Hoover HE, Thuerauf DJ, Glembotski CC. Mimicking phosphorylation of alphaB-crystallin on serine-59 is necessary and sufficient to provide maximal protection of cardiac myocytes from apoptosis. Circ Res 2003;92:203-211.
22. Pandey P, Farber R, Nakazawa A, Kumar S, Bharti A, Nalin C, et al. Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene 2000;19:1975-1981.
23. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004;113:115-123.
24. McClung JM, Kavazis AN, DeRuisseau KC, Falk DJ, Deering MA, Lee Y, et al. Caspase-3 regulation of diaphragm myonuclear domain during mechanical ventilation-induced atrophy. Am J Respir Crit Care Med 2007;175:150-159.
25. Rachek LI, Musiyenko SI, LeDoux SP, Wilson GL. Palmitate induced mitochondrial deoxyribonucleic acid damage and apoptosis in l6 rat skeletal muscle cells. Endocrinology 2007;148:293-299.
26. Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004;194:10-23.
27. Allen DL, Harrison BC, Maass A, Bell ML, Byrnes WC, Leinwand LA. Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J Appl Physiol 2001;90:1900-1908.
28. Meador BM, Huey KA. Glutamine preserves skeletal muscle force during an inflammatory insult. Muscle Nerve 2009;40:1000-1007.
29. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57:525-528.
30. Liantonio A, Giannuzzi V, Cippone V, Camerino GM, Pierno S, Camerino DC. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2{thorn}-release system. J Pharmacol Exp Ther 2007;321:626-634.
31. England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors-simvastatin and pravastatin. Aust NZ J Med 1995;25:374-375.
32. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585.
33. Sinzinger H, Schmid P, O'Grady J. Two different types of exerciseinduced muscle pain without myopathy and CK-elevation during HMG-co-enzyme-A-reductase inhibitor treatment. Atherosclerosis 1999;143:459-460.
34. Bergman M, Salman H, Djaldetti M, Alexandrova S, Punsky I, Bessler H. Ultrastructure of mouse striated muscle fibers following pravastatin administration. J Muscle Res Cell Motil 2003;24:417-420.
35. Escobedo J, Pucci AM, Koh TJ. HSP25 protects skeletal muscle cells against oxidative stress. Free Radic Biol Med 2004;37:1455-1462.
36. Arya R, Mallik M, Lakhotia SC. Heat shock genes-integrating cell survival and death. J Biosci 2007;32:595-610.
37. Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest 2005;115:2633-2639.
38. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (Georgetown, Tex) 2006;5:2592-2601.
39. Jiang B, Xiao W, Shi Y, Liu M, Xiao X. Heat shock pretreatment inhibited the release of Smac/DIABLO from mitochondria and apoptosis induced by hydrogen peroxide in cardiomyocytes and C2C12 myogenic cells. Cell Stress Chaperones 2005;10:252-262.
40. Koh TJ. Do small heat shock proteins protect skeletal muscle from injury? Exerc Sport Sci Rev 2002;30:117-121.
41. Liu Y, Steinacker JM. Changes in skeletal muscle heat shock proteins: pathological significance. Front Biosci 2001;6:D12-D25.
42. Ghayour-Mobarhan M, Lamb DJ, Vaidya N, Livingstone C, Wang T, Ferns GA. Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study. Angiology 2005;56: 61-68.
43. Kretz A, Schmeer C, Tausch S, Isenmann S. Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol Dis 2006;21:421-430.
44. Pirillo A, Jacoviello C, Longoni C, Radaelli A, Catapano AL. Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells. Biochem Biophys Res Commun 1997;231:437-441.
45. Shin YO, Bae JS, Lee JB, Kim JK, Kim YJ, Kim C, et al. Effect of cardiac rehabilitation and statin treatment on anti-HSP antibody titers in patients with coronary artery disease after percutaneous coronary intervention. Int Heart J 2006;47:671-682.
46. Wang X, Tokuda H, Hatakeyama D, Hirade K, Niwa M, Ito H, et al. Mechanism of simvastatin on induction of heat shock protein in osteoblasts. Arch Biochem Biophys 2003;415:6-13.
47. Morton JP, Kayani AC, McArdle A, Drust B. The exercise-induced stress response of skeletal muscle, with specific emphasis on humans. Sports Med (Auckland, NZ) 2009;39:643-662.
48. Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol 2004;200:237-250.
49. Matzno S, Yasuda S, Juman S, Yamamoto Y, Nagareya-Ishida N, Tazuya-Murayama K, et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol 2005;57:1475-1484.
50. Mutoh T, Kumano T, Nakagawa H, Kuriyama M. Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts. FEBS Lett 1999;444:85-89.
51. Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 2005;314:1032-1041.
52. Lee HJ, Lee YJ, Kwon HC, Bae S, Kim SH, Min JJ, et al. Radioprotective effect of heat shock protein 25 on submandibular glands of rats. Am J Pathol 2006;169:1601-1611.
53. Vasconsuelo A, Milanesi L, Boland R. Participation of HSP27 in the antiapoptotic action of 17beta-estradiol in skeletal muscle cells. Cell Stress Chaperones 2010;15:183-192.
54. Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005;62:1709-1712.